Differential expression and bioinformation of lncRNA CASC15 in ameloblastoma

doi:10.19438/j.cjoms.2021.05.005

Abstract

Abstract: PURPOSE: To explore the expression of CASC15 and its mechanism in the development of ameloblastoma. METHODS: Second-generation high-throughput full-transcription sequencing data of 8 pairs of ameloblastoma and adjacent normal tissues were analyzed to screen out the target lncRNA CASC15. The co-expression mRNA with significant difference from CASC15 was screened by using DEseq2 algorithm. Gene Ontology (GO) analysis and signal pathway analysis were performed by comparing with the gene annotations in the GO database and KEGG database. The expression of CASC15 in ameloblastoma was detected by qRT-PCR. The data were analyzed with GraphPad Prism 8 software package. RESULTS: A total of 172 differentially expressed CASC15-related mRNA were screened out. GO analysis showed that the differentially co-expressed CASC15 mRNA was mainly involved in cell proliferation regulation, cell signal transduction, cell migration, angiogenesis and other biological behaviors. Pathway analysis showed that the co-expressed mRNA of CASC15 was mainly involved in pathway in cancer, Hedgehog, p53 as well as cancer-related signal pathway in osteocyte differentiation, cell cycle and so on. Five high core genes such as FGF18, EPCAM, PTCH1, SHH and GLI1, which were closely related to CASC15, screened by co-expression network analysis, which can be used to explore the mechanism of recurrence and invasion of ameloblastoma. qRT-PCR results showed that CASC15 was highly expressed in ameloblastoma, which was 11.41 times higher than that in adjacent normal tissues (P<0.0001), and 11.72 times higher than that in dental follicle tissues (P<0.0001). CONCLUSIONS: CASC15 is highly expressed in ameloblastoma, which may participate in the occurrence and development of ameloblastoma by regulating cell proliferation, cell migration and cell cycle.

Key words: Long non-coding RNA, CASC15, Ameloblastoma, Bioinformatics, Invasion

CLC Number:

R739.8

HE You-ya, ZHANG Yu, DAI Zhen-lin, LIN Cheng-zhong, CAO Wei, JI Tong. Differential expression and bioinformation of lncRNA CASC15 in ameloblastoma[J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(5): 411-416.

References

[1] McClary AC, West RB, McClary AC, et al. Ameloblastoma: a clinical review and trends in management[J]. Eur Arch Otorhinolaryngol, 2016, 273(7): 1649-1661.
[2] Effiom OA, Ogundana OM, Akinshipo AO, et al.Ameloblastoma: current etiopathological concepts and management[J]. Oral Dis, 2018, 24(3): 307-316.
[3] Wright JM, Vered M.Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: odontogenic and maxillofacial bone tumors[J]. Head Neck Pathol, 2017, 11(1): 68-77.
[4] 陶谦, 杨耀成. 2017年WHO成釉细胞瘤新分类的逻辑性与临床指导意义[J]. 广东牙病防治, 2020, 28(7): 416-420.
[5] 刘浏, 张新宇, 胡永杰, 等. 890例颌骨成釉细胞瘤发病构成比分析[J]. 口腔颌面外科杂志, 2015, 25(3): 213-215.
[6] Heikinheimo K, Kurppa KJ, Laiho A, et al.Early dental epithelial transcription factors distinguish ameloblastoma from keratocystic odontogenic tumor[J]. J Dent Res, 2015, 94(1): 101-111.
[7] Rinn JL, Kertesz M, Wang JK, et al.Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs[J]. Cell, 2007, 129(7): 1311-1323.
[8] Quinn JJ, Chang HY.Unique features of long non-coding RNA biogenesis and function[J]. Nat Rev Genet, 2016, 17(1): 47-62.
[9] Bai Y, Zhang G, Cheng R, et al.CASC15 contributes to proliferation and invasion through regulating miR-766-5p/KLK12 axis in lung cancer[J]. Cell Cycle, 2019, 18(18): 2323-2331.
[10] He T, Zhang L, Kong Y, et al.Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis[J]. Int J Oncol, 2017, 51(6): 1722-1730.
[11] Zhang Y, Liu B, Jiang T, et al.Long non-coding RNA CASC15 promotes proliferation and induces apoptosis of cervical cancer cells through targeting miR-101-3p[J]. Eur Rev Med Pharmacol Sci, 2020, 24(17): 8627.
[12] Sheng L, Wei R.Long non-coding RNA-CASC15 promotes cell proliferation, migration, and invasion by activating Wnt/β-catenin signaling pathway in melanoma[J]. Pathobiology, 2020, 87(1): 20-29.
[13] Love MI, Huber W, Anders S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J]. Genome Biol, 2014, 15(12): 550-570.
[14] Draghici S, Khatri P, Tarca AL, et al.A systems biology approach for pathway level analysis[J]. Genome Res, 2007, 17(10): 1537-1545.
[15] Benjamini Y, Hochberg Y.Controlling the false discovery rate: a practical and powerful approach to multiple testing[J]. J Roy Stat Soc B, 1995, 57(1): 289-300.
[16] Prieto C, Risueño A, Fontanillo C, et al.Human gene coexpression landscape: confident network derived from tissue transcriptomic profiles[J]. PLoS one, 2008, 3(12): e3911-e3950.
[17] Ravasz E, Somera AL, Mongru DA, et al.Hierarchical organization of modularity in metabolic networks[J]. Science, 2002, 297: 1551-1555.
[18] Wu Q, Xiang S, Ma J, et al.Long non-coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1[J]. Mol Oncol, 2018, 12(6): 799-813.
[19] Zhang Y, Zhang L, Lu S, et al.Long non-coding RNA CASC15 promotes intrahepatic cholangiocarcinoma possibly through inducing PRDX2/PI3K/AKT axis[J]. Cancer Res Treat, 2021, 53(1): 184-198.
[20] Sun J, Xiong Y, Jiang K, et al.Hypoxia-sensitive long noncoding RNA CASC15 promotes lung tumorigenesis by regulating the SOX4/β-catenin axis[J]. J Exp Clin Cancer Res, 2021, 40(1): 12-45.
[21] Zhang H, Wang J, Ren T, et al.LncRNA CASC15 is upregulated in osteosarcoma plasma exosomes and CASC15 knockdown inhibits osteosarcoma progression by regulating miR-338-3p/RAB14 axis[J]. Onco Targets Ther, 2020, 13: 12055-12066.
[22] Yin Y, Zhao B, Li D, et al.Long non-coding RNA CASC15 promotes melanoma progression by epigenetically regulating PDCD4[J]. Cell Biosci, 2018, 8: 42-69.
[23] Yu X, Wang Z, Han C, et al.LncRNA CASC15 functions as an oncogene by sponging miR-130b-3p in bladder cancer[J]. Eur Rev Med Pharmacol Sci, 2019, 24(13): 7203-7209.
[24] Shi Y, Gao S, Zheng Y, et al.LncRNA CASC15 functions as an unfavorable predictor of ovarian cancer prognosis and inhibits tumor progression through regulation of miR-221/ARID1A axis[J]. Onco Targets Ther, 2019, 12: 8725-8736.
[25] Russell MR, Penikis A, Oldridge DA, et al.CASC15-S is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus[J]. Cancer Res, 2015, 75(15): 3155-3166.
[26] Marie-Egyptienne DT, Lohse I, Hill RP.Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia[J]. Cancer Lett, 2013, 341(1): 63-72.
[27] Kumamoto H, Ohki K, Ooya K.Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas[J]. J Oral Pathol Med, 2002, 31(1): 28-34.
[28] 钟鸣, 李自娟, 王洁, 等. 成釉细胞瘤的侵袭性生物学行为研究[J]. 中华口腔医学杂志, 2004, 39(1): 45-48.
[29] Chen WL, Ouyang KX, Li HG, et al.Expression of inducible nitric oxide synthase and vascular endothelial growth factor in ameloblastoma[J]. J Craniofac Surg, 2009, 20(1): 171-177.
[30] Sweeney RT, McClary AC, Myers BR, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas[J]. Nat Genet, 2014, 46(7): 722-725.
[31] Meek DW.Regulation of the p53 response and its relationship to cancer[J]. Biochem J, 2015, 469(3): 325-346.
[32] Shaikh Z, Niranjan KC.Cell cycle aberration in ameloblastoma and adenomatoid odontogenic tumor: as evidenced by the expression of p53 and survivin[J]. Indian J Dent Res, 2015, 26(6): 565-570.
[33] Kearns AE, Khosla S, Kostenuik PJ.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease[J]. Endocr Rev, 2008, 29(2): 155-192.
[34] Sandra F, Hendarmin L, Kukita T, et al.Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone[J]. Oral Oncol, 2005, 41(6): 637-644.
[35] 何优雅, 季彤. SMO基因突变在成釉细胞瘤中的研究进展[J]. 国际口腔医学杂志, 2020, 47(1): 69-73.